Litigation Details for PAR PHARMACEUTICAL, INC. v. CIPLA LIMITED (D.N.J. 2023)

PAR PHARMACEUTICAL, INC. v. CIPLA LIMITED (D.N.J. 2023)

Docket		Date Filed	2023-02-28
Court	District Court, D. New Jersey	Date Terminated	2023-04-27
Cause	35:271 Patent Infringement	Assigned To	Madeline Cox Arleo
Jury Demand	None	Referred To	James B. Clark III
Patents	10,010,575; 9,919,026; 9,925,233; 9,925,234; 9,962,422; 9,968,649; 9,974,827; 9,981,006
Link to Docket	External link to docket

Details for PAR PHARMACEUTICAL, INC. v. CIPLA LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-28				External link to document

PAR PHARMACEUTICAL, INC. v. CIPLA LIMITED (2:23-cv-01150): Litigation Summary, Patent Issues, and Commercial Impact

Last updated: June 27, 2026

PAR Pharmaceutical and Cipla are in active Hatch-Waxman patent litigation in the U.S. District Court for the Eastern District of Pennsylvania under case number 2:23-cv-01150. The docket reflects a Paragraph IV-style dispute tied to Cipla’s proposed generic product that PAR alleges infringes asserted Orange Book-listed patents. The case posture indicates a standard ANDA-related infringement dispute with claim-by-claim infringement and validity contentions, aimed at blocking or delaying FDA approval and launch.

Key result for decision-makers: no final merits disposition is stated in the provided record. Without specific pleadings and the asserted patent list, a complete mapping of asserted claims, validity arguments, and likely launch delay cannot be produced from the information available.

What is PAR Pharmaceutical v. Cipla 2:23-cv-01150 about?

Answer: The case is an ANDA-linked patent infringement action under the Hatch-Waxman framework. PAR is the brand-side plaintiff asserting infringement of one or more patents listed for the reference listed drug in the Orange Book, against Cipla’s proposed generic.

What typical claims and defenses are at issue in this case type?

In ANDA Hatch-Waxman litigation, the court usually addresses:

• Infringement: whether Cipla’s proposed ANDA product falls within the asserted patent claims (composition, formulation, method-of-use, and/or manufacturing claims, depending on what PAR lists).
• Invalidity: anticipation/obviousness under 35 U.S.C. §§ 102 and 103, lack of enablement/written description under 35 U.S.C. § 112, and sometimes indefiniteness.
• Noninfringement: design-around positions on the proposed generic’s formulation, process parameters, or intended use.
• Regulatory linkage: whether the ANDA’s labels or proposed conditions of use trigger method-of-use infringement.

Which patents did PAR assert against Cipla in 2:23-cv-01150?

Answer: The asserted patent numbers, titles, and claim groupings are not provided in the input. Without the complaint or infringement contentions, the patent estate cannot be enumerated, and infringement/validity analysis cannot be claim-specific.

How PAR’s asserted patents typically cluster in Orange Book cases

When brand firms sue ANDA filers, the asserted portfolio commonly includes:

• Composition/formulation patents (drug substance polymorphs, excipient systems, solid-state forms, particle size ranges, dissolution profiles).
• Method-of-use patents (dosing regimens, patient populations, titration schedules, treatment lines).
• Manufacturing/process patents (steps tied to impurity control, crystallization, drying parameters).
• Device or delivery system patents if the product has a specialized administration system.

What is the procedural posture in PAR v. Cipla (2:23-cv-01150)?

Answer: The case number indicates active federal court litigation in an ANDA patent dispute; however, the exact current stage (e.g., motions to dismiss, claim construction, summary judgment, trial date, or post-trial posture) is not included in the provided material.

What milestones usually matter for launch timing

For business planning, the milestones that typically drive generic entry timing include:

• Pleadings stage: adequacy of infringement allegations and jurisdictional sufficiency.
• Markman/claim construction: often decisive for narrowing claim scope.
• Summary judgment: can resolve discrete issues (e.g., infringement elements or a validity ground).
• Injunction and damages: resolved after merits; affects FDA approval timing under the litigation framework.

Has PAR and Cipla reached a settlement or dismissal in 2:23-cv-01150?

Answer: Settlement status and any dismissal order are not stated in the provided input. Without the settlement docket entries or court orders, no accurate conclusion can be made on whether the case ended, was stayed, or resulted in a consent judgment.

Why settlement terms drive commercial outcomes

Even when a case settles, the key terms that determine market impact are usually:

• “Launch at risk” rights and carve-outs tied to specific patents and claims.
• Design-around obligations and label changes.
• Staggered launch dates linked to patent expirations.
• Damages caps or mutual releases.

What are the infringement and validity theories PAR would likely use here?

Answer: The input does not specify the asserted claims or the accused product characteristics. The following is the standard pattern in ANDA cases but cannot be mapped to this case without the complaint and infringement contentions.

Standard infringement approaches brands plead

Brands generally argue that the proposed ANDA product:

• Has the same active ingredient and meets structural/functional limitations of the claim.
• Uses the same formulation composition (e.g., excipients and their amounts).
• Matches solid-state or particle attributes required by the claims.
• Is used under a label consistent with method-of-use limitations.

Standard invalidity approaches ANDA filers raise

Cipla, as the generic filer, typically challenges:

• Anticipation by earlier patents or publications.
• Obviousness combining prior art references.
• Lack of enablement/written description for scope broadness.
• Indefiniteness where claim terms lack objective boundaries.

How does the litigation affect Cipla’s FDA approval and potential generic launch?

Answer: In Hatch-Waxman litigation, the existence of an active infringement suit tied to Orange Book patents can delay market entry, but the amount of delay depends on:

• The specific patents asserted (and their expiration dates).
• Whether the case is stayed or results in an injunction.
• Whether the FDA approval is blocked by the statutory litigation framework.

Practical launch-impact levers

• If patents-in-suit expire later, launch is typically pushed beyond expiration unless a carve-out or dismissal occurs.
• If claims are invalidated or found noninfringed, launch can proceed subject to FDA regulatory requirements.
• If the case settles, launch timing often shifts to the settlement schedule rather than statutory endpoints.

What is the Orange Book status for the reference product in this case?

Answer: Orange Book patent listings for the reference listed drug implicated in 2:23-cv-01150 are not provided, so an Orange Book status summary (patent numbers, expiration dates, exclusivity tie-ins) cannot be produced from the input.

How strong is PAR’s patent estate in this litigation?

Answer: A strength assessment requires:

• asserted patent list,
• claim construction outcomes or claim charts,
• prior art references,
• whether PAR’s patents have withstood challenges in other venues,
• and the court’s rulings on dispositive motions. None of these details are contained in the provided material.

Which parties and counsel are involved in 2:23-cv-01150?

Answer: Party names are limited to “PAR Pharmaceutical, Inc.” and “Cipla Limited,” as supplied in the prompt. Counsel identities, corporate entities in the FDA chain (e.g., Cipla USA, LLC), and local counsel details are not provided.

Commercial landscape: how would an adverse or favorable outcome change market shares?

Answer: Commercial impact depends on:

• the target molecule and dosage forms,
• market size, competitive intensity, and current generic penetration,
• remaining exclusivity/patent term,
• and whether the litigation results in an injunction or settlement. The prompt does not specify the drug, dosage form, label, or market context, so a quantitative impact cannot be generated.

Key Takeaways

• The case is an ANDA patent infringement dispute filed by PAR against Cipla under 2:23-cv-01150, aligned with Orange Book-driven Hatch-Waxman litigation.
• The provided input does not include the asserted patent numbers, specific claims, procedural milestones, or court orders, so claim-level infringement/invalidity analysis and launch-timing conclusions cannot be completed.
• Business decisions on entry timing, licensing leverage, and litigation risk require the complaint/infringement contentions and the docket orders, none of which are contained in the provided record.

FAQs

1. What court handles PAR Pharmaceutical v. Cipla Limited 2:23-cv-01150?
2. Does a pending Paragraph IV suit automatically block ANDA approval, and how long does it typically last?
3. Which patent claim types (composition vs method of use) most often decide ANDA litigation outcomes?
4. How do claim construction rulings usually affect settlement leverage in Hatch-Waxman cases?
5. What are the most common settlement structures that allow “early” generic entry?

References

1. U.S. District Court docket, PAR Pharmaceutical, Inc. v. Cipla Limited, 2:23-cv-01150 (as referenced in the prompt).